# Neoadjuvant Therapy Combined With Trastuzumab Rezetecan and Toripalimab for HR+/HER2-low Breast Cancer (NEOTORCH-BREAST 08)

> **NCT07383818** · PHASE2 · RECRUITING · sponsor: **First Affiliated Hospital of Zhejiang University** · enrollment: 111 (estimated)

## Conditions studied

- HR Positive/HER2 Low Breast Cancer

## Interventions

- **DRUG:** Neoadjuvant therapy combined with Trastuzumab Rezetecan and Toripalimab
- **DRUG:** Neoadjuvant Chemotherapy in Combination with Toripalimab
- **DRUG:** Neoadjuvant Chemotherapy

## Key facts

- **NCT ID:** NCT07383818
- **Lead sponsor:** First Affiliated Hospital of Zhejiang University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-02-01
- **Primary completion:** 2028-02-01
- **Final completion:** 2031-02-01
- **Target enrollment:** 111 (ESTIMATED)
- **Last updated:** 2026-02-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07383818

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07383818, "Neoadjuvant Therapy Combined With Trastuzumab Rezetecan and Toripalimab for HR+/HER2-low Breast Cancer (NEOTORCH-BREAST 08)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT07383818. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*